The German Institute for Quality and Efficiency in Health Care (IQWiG) has examined the pros and cons of biomarker-based ...

There were no cases of HER2 positivity among patients with gliomas, sarcomas, small cell lung cancer, gastrointestinal stromal tumors, thyroid carcinoma, uterine sarcoma, thymic carcinoma, and Merkel ...

The FDA has approved Swiss pharmaceutical company Roche’s first companion diagnostic for identifying those patients with HER2 low-metastatic breast cancer who are eligible for ENHERTU.

Immunohistochemical evaluation of HER2/ neu expression and FISH analysis of HER2 amplification were performed in 320 patients with AOC.

HER2/ neu positivity was assessed using the updated recommendations published by Ellis et al, [12] with IHC 2+ (borderline positivity) corresponding to a weak to moderate complete membrane ...

HER2/neu Expression and Hormonal Therapy in Early Breast Cancer: Can Muddy Waters Become Clear? Authors: Gianluigi Ferretti, Serena Di Cosimo, Diana Giannarelli, Paolo Carlini, Paola Papaldo, Andrea ...

Examples of specific types of immunotherapies include dendritic cell therapy (sipuleucel-T), adoptive T-cell therapy (CAR-T), antibody therapy (anti-CD47, anti-GD2, anti-CD52, anti-PD-L1, anti-SLAMF7, ...

Amplification of the human epidermal growth factor receptor 2 (HER2, Erb B2) gene leads to persistent activation of signaling pathways that enhance cell proliferation, resistance to apoptosis signals, ...

HER2/neu primarily activates the MAPK and PI3K pathways, contributing to malignant transformation when overexpressed or amplified.

$2.25 Million Research Collaboration Focused on Understanding and Treating Lung Cancers Harboring HER2 Mutations; call for Requests for Proposals NEW YORK, June 17, 2025 /PRNewswire/ -- The Lung ...

“The Series D financing represents further endorsement of Neuron23’s industry-leading approach, which leverages state-of-the-art precision medicine and patient identification to deliver NEU ...

Bayer and Boehringer present data on competing oral HER2 drugs at WCLC, as they run phase 3 trials in NSCLC with HER2 activations.